Copper Peptides

"Copper peptide" on a skin-care label almost always means one molecule: GHK-Cu, the tripeptide glycyl-histidyl-lysine with a copper ion bound to it. It was found in human blood more than fifty years ago, and has been used in cosmetics since the late 1980s[1]. Few cosmetic peptides have been studied for as long, and the list of effects attributed to it is long: collagen synthesis, wound healing, blood vessel growth, protection against oxidative damage and control of thousands of genes[2].

Most of that list, however, comes from cells and animals, and the evidence that a cream containing GHK-Cu does anything visible to human skin is much thinner. This page follows that gap. It starts with what the molecule is and how it holds copper, then looks at the laboratory and gene-expression findings, and ends with the human trials, which turn out to be few, and with the question of who has produced most of the evidence.

GHK and its copper

GHK was found by Loren Pickart in 1973, as an activity in human plasma albumin that caused liver tissue from older people to make proteins in the way younger tissue does. The activity was later traced to the tripeptide glycyl-histidyl-lysine[3]. According to Pickart's measurements, its level in plasma is about 200 ng/mL (10⁻⁷ M) at age 20 and falls to about 80 ng/mL by age 60[3].

The peptide binds copper(II) tightly. In the complex, the copper ion is held by three nitrogen atoms: one from the imidazole ring of histidine, one from the free amino group of glycine, and one from the peptide bond between glycine and histidine, which gives up its hydrogen to bind the metal[3]. The structure has been studied by X-ray crystallography and several kinds of spectroscopy[3]. GHK binds copper slightly more strongly than albumin, the main copper carrier in blood, with binding constants of 10^16.44 and 10^16.2 respectively, so it can take copper from albumin[3]. Once bound, the copper no longer takes part in the redox reactions that make free copper ions harmful[3]. This is why GHK-Cu is classed among the "carrier peptides" in cosmetics, those that deliver trace elements such as copper and manganese to the skin[1].

The sequence Gly-His-Lys occurs in the α2 chain of type I collagen and in SPARC, a protein abundant in tissues under repair. When these proteins are broken down after an injury, GHK is released at the site[2]. In this picture GHK is an early signal of damage, much like the collagen fragment Pro-Hyp described on the collagen peptides page.

In cells and animals

The best-established effects of GHK-Cu are on fibroblasts, the cells that build the connective tissue of skin. In the 1980s and 1990s a French group led by François-Xavier Maquart found that GHK-Cu at 1–10 nM stimulates both the synthesis and the breakdown of collagen and glycosaminoglycans, and changes the activity of matrix metalloproteinases (MMPs), the enzymes that degrade the matrix, as well as of their inhibitors (TIMPs)[3]. A 2016 study in New Zealand repeated this in human adult skin fibroblasts. At 0.01–100 nM, GHK-Cu increased the production of collagen and elastin, and raised the expression of TIMP1 at every concentration tested[4]. The authors read this as a shift of the balance between matrix breakdown and matrix building towards building[4].

Animal studies point in the same direction. GHK-Cu applied to wounds sped up healing in rabbits, in healthy, diabetic and ischaemic wounds in rats, and in paw-pad wounds in dogs; it raised the levels of antioxidant enzymes and the growth of new blood vessels in the wounds[3]. Judging by the authors of the studies cited, much of this work was done by veterinary and university groups rather than by the discoverer's own laboratory[3]. There is also a practical weakness: GHK is quickly broken down by carboxypeptidases, and the fluid of chronic wounds such as diabetic ulcers or bedsores degrades it rapidly[2].

Further claims rest on less. GHK slowed the growth of some cancer cell lines, reduced signs of anxiety and pain in rats given injections, and protected the lungs of mice from induced injury[2]. These are single studies in cells or animals, and none of them has been tested in people.

The gene story

Since about 2010 the claims for GHK have grown from wound healing to the control of thousands of genes. This story has one independent starting point. In 2012 a team from Boston University and other centres studied lungs removed from patients with severe chronic obstructive pulmonary disease (COPD)[5]. They found 127 genes whose activity changed with the degree of emphysema in different parts of the same lung. Genes for inflammation went up, and genes for tissue repair, including the TGF-β pathway, went down[5].

They then searched the Connectivity Map, a public database run by the Broad Institute that records how the activity of genes in cultured cancer cell lines changes after treatment with more than a thousand compounds[5]. GHK was one of the compounds whose pattern was the reverse of the emphysema pattern. In the database, GHK had been tested at 1 µM[5]. The team confirmed the finding in human lung fibroblasts at 0.1 and 10 nM. GHK switched on repair-related genes there too, and it restored the ability of fibroblasts from COPD patients to contract and remodel a collagen gel, as TGF-β itself did[5]. The authors called for further studies of the mechanism and of whether reversing the gene pattern affects the disease[5]. Boston University declared intellectual property related to the work[5].

Pickart and colleagues then took the same database further. By their count, GHK changes the activity of 31.2% of human genes by at least 50%, switching more of them on than off[2]. They describe this as "resetting the gene activity back to health"[2]. That is their interpretation, not a measured outcome. The data show changes in messenger RNA in cultured cells, and whether a given change is good or bad for a person depends on the tissue and the context. The concentration used in the database, 1 µM, is also about ten times the level of GHK in young plasma.

On human skin

To act on the skin, GHK-Cu first has to get into it. That is harder than it sounds. The complex is very hydrophilic: its distribution coefficient between octanol and water (log D) is about −2.5, while molecules that pass easily through the outer layer of skin have values between 1 and 3[4]. Laboratory studies of human skin suggest that some GHK-Cu does penetrate[2], and newer work shows that larger molecules can pass the barrier of dry or aged skin more easily than once thought[1]. A common workaround is to make the peptide fatty. Palmitoyl-GHK, GHK with a palmitic acid attached, is one of the active ingredients in the commercial blend Matrixyl 3000[1][4].

The clinical evidence is short enough to list in full. The same handful of studies appears in every review[3][2][1][6]:

Abdulghani: one month according to Pickart et al. 2015 and Schagen 2017, twelve weeks according to Pickart and Margolina 2018[3][1][2]. Krüger et al. (2003) also reported a small pilot study in German journals[2].

Only the last study was a randomised, double-blind trial published in a journal with its methods and data, so it deserves a closer look[4]. Forty women aged 40 to 65 applied a serum containing GHK-Cu in a lipid nano-carrier to the right side of the face for eight weeks. On the left side they applied a comparison product: half of the women, chosen at random, used a Matrixyl 3000 product and the other half the plain serum without GHK-Cu. A single large wrinkle at the corner of the eye was measured with a 3D optical scanner. Compared with Matrixyl 3000, the GHK-Cu serum reduced wrinkle volume by a further 31.6%; compared with the plain serum, it reduced wrinkle volume by 55.8% and depth by 32.8%[4].

Three details limit what this shows. The plain serum lacked both the GHK-Cu and the nano-carrier, so the trial cannot separate the effect of the peptide from that of the lipid carrier. Even the plain serum reduced wrinkle volume by about 15%, so a cream without the active ingredient also changes the result. And the study was funded by the company that supplied the test serum; the authors state that the company had no role in the analysis or writing[4].

Independent reviews of skin trials find little to add. A 2026 meta-analysis of randomised trials of peptides for skin ageing found only two good-quality trials of peptide creams, and GHK-Cu was tested in neither[7]. Reviews of cosmetic peptides also note that many trials tested finished products containing other active ingredients, so the contribution of the peptide itself cannot be separated[1]. Copper peptides are also sold for hair growth. A 2026 review cites laboratory work in which GHK-Cu lengthened isolated human hair follicles at very low concentrations[6]. In another review, the sources given for the claim that it works as well as minoxidil are a conference abstract on a face cream, a review and a study of stem cells in a gel[1].

Who makes the claims

Much of what is written about GHK-Cu traces back to one source. The most widely cited reviews were written by Loren Pickart and his colleagues at the research department of Skin Biology[3][2], a company Pickart founded in 1992 that sells copper peptide skin products[8]. Both reviews state that the authors have no conflict of interest[3][2]. Their descriptions of the human studies are also more generous than the sources. The 2015 review calls the studies "placebo-controlled"[3], although the list above contains a pilot comparison of active creams, two conference abstracts and a book chapter. The 2018 review gives the duration of the Abdulghani study as twelve weeks rather than one month[2][3]. The same results reappear in a 2026 review in a dermatology journal, which states that experimental and clinical studies "consistently demonstrate" the importance of GHK-Cu for the skin[6].

This does not make the laboratory findings wrong. Several of them were made by independent groups, and GHK's effects on fibroblasts were confirmed by the New Zealand study[4]. The reviews go further and propose GHK as a dietary supplement and as a treatment for anxiety, pain and COPD[2], none of which they support with trials in people. GHK-Cu is also injected in anti-ageing clinics, although it has no approval from the US Food and Drug Administration for injectable use[6]. In cosmetics, GHK-Cu appears to be well tolerated: in the 2016 trial only one of 40 participants reacted, and she reacted to the Matrixyl product as well[4].

So the gap this page set out to follow is real. GHK-Cu is a natural fragment of the body's own matrix, it binds copper in a well-understood way, and it reliably changes the behaviour of fibroblasts in a dish and of wounds in animals. Whether a cream containing it makes a visible difference to human skin rests on one small trial and a set of reports that were never published in full.

References

1. Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics 4:16. DOI: 10.3390/cosmetics4020016
2. Pickart L, Margolina A (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 19:1987. DOI: 10.3390/ijms19071987
3. Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International 2015:648108. DOI: 10.1155/2015/648108
4. Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z (2016). Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science 4:166. DOI: 10.4172/2329-8847.1000166
5. Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, Suzuki M, Gosselink JV, Liu G, Alekseyev YO, Xiao J, Zhang X, Hayashi S, Cooper JD, Timens W, Postma DS, Knight DA, Lenburg ME, Hogg JC, Spira A (2012). A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine 4:67. DOI: 10.1186/gm367
6. Sarbaziha R, Goldberg DJ (2026). Copper peptides in regenerative aesthetic dermatology. Dermatological Reviews 7:e70067. DOI: 10.1002/der2.70067
7. Nukaly HY, Halawani IR, Irtaza HM, Alturkistani T, Serafi MR, Alhawsawi W, Bogari HO, Ahmed FA, Alhaddad Y, Shadid A, Alharithy R, Jfri A (2026). Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine 13:1618306. DOI: 10.3389/fmed.2026.1618306
8. Copper Development Association (June 2006). Copper your skin. Innovations. copper.org